In the first of three webinars on biologics, Sandy Johnson talked with Ed Silverman, Pharmalot writer with The Boston Globe’s Stat, and Dr. Kathryn C. Zoon, chief of Cytokine Biology in the NIAID, a branch of the National Institutes of Health.
Regulation & Prevalence of Bio-Tech Drugs
Patricia Zettler, associate chief counsel at FDA for four years and now an associate law professor at Georgia State University, and Sarah Karlin, POLITICO Pro health care reporter.
What’s Next? Biosimilars
Michael Kleinrock, director of research development for IMS Institute For Healthcare Informatics and Dr. Jeremy Greene of Johns Hopkins University
Highlights: Future of Biosimilar Drugs
Highlights from What's Next? Biosimilars: The Future of Biosimilar Drugs in the U.S